Akèy › Metiyè › Medical Scientists, Except Epidemiologists › Waltham, MA
Medical Scientists, Except Epidemiologists nan Waltham, MA: Salè H-1B
60 aplikasyon kondisyon travay pou okipasyon sa a ak yon sit travay nan Waltham, MA. Salè baz medyàn ofri $125,330; mwatye mitan $109,024–$147,675.
Demann (LCA)60
Salè medyan ofri$125,330
Mwatye salè yo$109,024–$147,675
10yèm–90yèm pousantaj$88,466–$168,442
Pa nivo salè
| Nivo revni | Salè medyan |
|---|---|
| Nivo I (antre) | $115,000 |
| Nivo II (kalifye) | $116,002 |
| Nivo III (eksperyans) | $133,000 |
| Nivo IV (plen kompetans) | $164,116 |
Depatman Travay la etabli kat nivo salè prevanlan pou chak okipasyon ak zòn, soti nan Nivo I (antre) rive nan Nivo IV (plen kompetans). Anplwayè a chwazi nivo ki koresponn ak kondisyon travay la.
Anplwayè yo
| Anplwayè | LCA | Salè medyan |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 10 | $159,125 |
| Sanofi Pasteur Inc. | 9 | $100,500 |
| Seqirus Inc. | 9 | $120,000 |
| GlaxoSmithKline LLC | 6 | $144,898 |
| Sanofi US Services Inc. | 4 | $108,284 |
| Bioverativ Therapeutics, Inc. | 2 | $124,051 |
| Xilio Development Inc. | 2 | $122,000 |
| Apellis Pharmaceuticals Inc. | 2 | $155,732 |
| Trinity Partners, LLC | 2 | $147,500 |
| Sanofi Vaccines US Inc. | 2 | $114,657 |
| Orionis Biosciences Inc. | 1 | $180,000 |
| Sarepta Therapeutics, Inc. | 1 | $150,000 |
| AMAG Pharmaceuticals, Inc. | 1 | $164,116 |
| RVAC Medicines (US), Inc. | 1 | $110,000 |
| Photys Therapeutics Inc. | 1 | $88,962 |
| Certara USA Inc. | 1 | $120,000 |
| Children's Hospital Corporation | 1 | $73,000 |
| Visterra, Inc. | 1 | $285,000 |
| Viridian Therapeutics, Inc. | 1 | $255,000 |
| Yoh, A Day & Zimmermann Company | 1 | $116,002 |
| Lynxkite Inc. | 1 | $144,000 |
| Dash Bio, Inc. | 1 | $107,000 |
Tit travay
- Investigator I4
- Associate Director, Precision Medicine2
- Scientist2
- Manager Quantitative Clinical Pharmacology2
- mRNA - Bioassay Senior Scientist2
- Scientist I2
- Senior Scientist2
- Director, Translational Biology1
- Principal Engineer, Manufacturing Sciences and Technology1
- Associate Director, Pharmacovigilance Scientist & Operations1
- Sr. Research Associate1
- Investigation I1
- Principal Scientist1
- Senior Research Associate Scientist II, Formulation Research1
- mRNA - Scientist, Delivery and Formulation Development1
Salè yo se fen ki pi ba nan salè yo ofri sou chak aplikasyon, konvèti nan yon montan anyèl; estatistik yo itilize sèlman aplikasyon tan plen sètifye. Yon LCA pa yon apwobasyon visa epi yon sèl LCA ka kouvri plizyè pozisyon. Sous: Depatman Travay Etazini, Done Divulgasyon LCA OFLC, ane fiskal 2023–2026 (dènye desizyon Jun 30, 2026).